Abstract OTK18 is a C 2 H 2 type zinc finger protein expressed by human macrophages following HIV infection.
Introduction
Human immunodeficiency virus-1 (HIV-1) infects and is disseminated throughout the body by CD4 + T-cells and mononuclear phagocytes (MP), which include infiltrating perivascular and resident tissue macrophages and microglia (Hussain and Lehner 1995; Gendelman et al. 1997) . Infection of brain MP plays a central role in the pathogenesis of HIV-1-associated dementia (HAD) and HIV-1 encephalitis (HIVE), the pathological correlate of HAD. Generally, HIV-1 replication is under tight control in the brain for years following the initial infection (Navia et al. 1986 ). What initiates the high level of viral replication seen late in the course of the disease is unknown. Neurological disease is likely to be the result of complex interactions between viral and host cellular factors.
OTK18, a protein produced during HIV-1 infection of MP, suppresses HIV-1 replication through the viral LTR (Carlson et al. 2004a ) and may play an important role in the interaction of viral and host cell factors leading to HAD and HIVE. OTK18 contains 13 C 2 H 2 -type zinc fingers and is characterized as a repressive transcription factor (Saito et al. 1996 ). OTK18's repressive activity lies within amino acids 26-89 located within a conserved Krüppel associated box (KBAB), a repression domain encoded by a number of transcription factors. OTK18 gene expression is inducible by HIV-1 infection in macrophages but is tightly regulated and is only detectable in the cytoplasm of brain macrophages in severe HIVE brains (Carlson et al. 2004b ). This observation suggests that HIV-1-induced OTK18 expression in HIVE brains might be used as a surrogate marker for HAD. In this paper, we developed an ELISA for OTK18 detection to examine OTK18 levels in both plasma and cerebrospinal fluid (CSF) collected from uninfected and HIV + patients. Our results indicate that OTK18 levels decrease in HIV + patients in both the plasma and CSF. Furthermore, decreased OTK18 levels correlate with decreased CD8 + cell count in the plasma independent of HIV infection.
Methods

Study population
Twenty-three HIV-1-seronegative and 21 HIV-1-seropositive subjects paired plasma and CSF samples were obtained at University of California San Francisco. Paired CSF and plasma samples were derived from participants in two longitudinal cohort studies approved by the University of California-San Francisco Committee on Human Research. Informed consent was obtained from all subjects (and from the durable power of attorney of an individual with stage 2 ADC). The CDC stages of the HIV + patients were all 0 except one case, which was 2. Subjects with active CNS diseases other than ADC were excluded (Spudich et al. 2005a ).
Plasma and CSF processing and analysis
The CSF and plasma were collected at the same time and were obtained from a depository for general study purposes and were processed in standardized fashion as previously described (Price and Deeks 2004) . The specimens were kept frozen at −80°C and stored for less than 5 years. To avoid the repeated freezing of the samples, aliquots were made at the initial storage. CSF and plasma were analyzed for HIV RNA concurrently. CSF cell counts, CD4 + and CD8 + T lymphocyte counts, as well as differential protein and albumin blood levels were measured using routine clinical methods in the San Francisco General Clinical Laboratory. HIV-1 RNA levels were measured in cell-free CSF and plasma using Roche Amplicor HIV-1 Monitor assay (versions 1.0 and 1.5; Roche Diagnostic systems) with standard and ultrasensitive extraction methods, as appropriate, according to the manufacturer's guidelines. HIV-1 RNA concentrations were transformed to log 10 values for all calculations (Spudich et al. 2005a, b) .
OTK18 monoclonal antibody (mAb) biotinylation OTK18 mAbs were generated by s.c. injection of Histagged OTK18 (1-178) truncated recombinant protein purified from Escherichia coli as described (Carlson et al. 2004a) . OTK18 monoclonal antibody 211-3.2-1 (5 mg) was biotinylated using EZ-Link Sulfo-NHS-Biotinylation kit (Pierce Biotechnology). The efficiency of the biotinylation was 3.72 mol biotin per mole of OTK18 mAb.
Luminescent OTK18 ELISA
Microtiter plates were coated with anti-OTK18 monoclonal antibody (211-3.1-1, 100 ng/well), blocked with blocking (Zhang et al. 1999) .
Statistical analyses
Pearson's correlation coefficient and scatter plot were first used to get an overview of the relationships between response and predictors. Multiple linear and logistic regressions (Kleinbaum et al. 1997; Hosmer and Lemeshow 2000) were applied to analyze plasma and CSF data, respectively, to study the effects of predictors on the level of OTK18 (Hosmer and Lemeshow 2000; Kleinbaum et al. 1997) . The procedures of stepwise model selection were used for both models to choose the "best" model to explain the relationship between response and predictors. Additional statistical techniques were applied to the two samples to deal with observations below the detectable limit (BDL), ranging between 0 and 10. For plasma data, there was one BDL observation, and we replaced its value with the average, which was 5. We then transformed the response into a logarithm scale in order to normalize the distribution. For CSF data, there were 14 BDL observations, and we categorized them into one level of response and modeled the data using logistic regression.
Results
Development of the OTK18 ELISA
The luminescent ELISA assay for quantification of OTK18 in plasma and CSF was optimized with purified OTK18 standard protein. The assay was performed against a standard curve of OTK18(1-178), with increasing concentrations of both capturing antibody and detection antibody. The resulting standard curve is biphasic and, for the purposes of OTK18 quantification, is split into a low-and a highstandard curve (Fig. 1a and b, respectively) . The standard curve can typically quantitate OTK18 levels from a 10-to 640-pM range, with a signal-to-noise ratio of 1.68 to 73.13 ART Currently under antiretroviral treatment, P-CSF protein CSF Fig. 2 Scatter plots of logarithm-scaled OTK18 with the values of CD4, CD8, and WBC. A linear regression line is also drawn for each plot and a Z′ factor of 0.07 to 0.97. These results indicate that this ELISA assay provides sensitivity and specificity sufficient for the clinical study.
Plasma OTK18 levels and demographic data analysis
The mean age (SD) for the 44 subjects is 42.9 (7.6) years. There are 37 men and seven women. Table 1 shows the summary statistics of age and gender for HIV + and HIV − subjects separately. Pearson's correlation coefficient and scatter plot were used to create an overview of the relationship between response and predictors. These methods show that log2(OTK18) is correlated with HIV status, CD4 value, CD8 value, and WBC value and are presented as scatter plots (see Table 2 and Fig. 2 (Fig. 3) .
Next, we applied multiple linear regression with stepwise model selection for analysis of plasma data. After adjusting for age (categorized as two groups: ≥45 and <45) and gender, we found HIV status and CD8 value to be the only predictors to significantly explain OTK18 measurements (Table 3 ). In particular, OTK18 levels of HIV + subjects are estimated to be about 16.4% (95% C.I. is from 3.6% to 76.5%) of OTK18 levels of HIV − subjects. OTK18 levels increase by about 30% when CD8 counts increase by 100 on average. The p values of HIV status and CD8 counts in the model are 0.02 and 0.007, respectively.
CSF OTK18 levels and demographic data analysis
For the CSF samples, the histogram of OTK18 shows that OTK18 distribution is a bimodal function on the logarithm scale and that the cutoff is around 3.4 (30 pM). In addition, over one third of OTK18 observations have missing values due to BDL. A common statistical technique is to model these BDL observations together as a single level of the Fig. 3 Boxplot of OTK18 with the status of HIV for plasma and CSF datasets. Please note that the y axes are displayed in a logarithm scale for both plots (Fig. 3) . Table 4 shows the frequency of subjects with different HIV status and the categorized OTK18 levels. Specifically, we can see that HIV + subjects are much less likely to have an OTK18 level of 30 or higher (14%) than are subjects who are HIV − (43%; p=0.03 by chi-square test). Please note that the predictor of CD8 value is not significant for this model (p value=0.40 in the model).
Discussion
Our results indicate that plasma OTK18 levels correlate best with CD8 counts and HIV status, while CSF levels correlate best with HIV status. This study indicates that CD8 + T-cells may play an additional role in the expression of OTK18 regulation. Antigen-specific CD8 + cytotoxic Tcells serve a prominent role in the control of HIV infection in both brain and peripheral tissues (Sewell et al. 2000) . Since we have observed OTK18 upregulation in brain perivascular macrophages in advanced HIV encephalitis (Carlson et al. 2004b) , it is possible that CD8 + T-cells infiltrate into the brain perivascular region and locally stimulate macrophages to express OTK18. It will be of interest to examine the neuropathological correlation of OTK18 expression in brain macrophages and CD8 + T-cells in HIV encephalitic cases.
Correlation of OTK18 levels with HIV status was predicted since OTK18 was originally cloned as HIV-1-inducible C 2 H 2 type zinc finger protein from monocytederived macrophages (Carlson et al. 2004a ). However, we did not predict that OTK18 levels would be negatively correlated with HIV status. These results suggest additional regulation for OTK18 expression in other peripheral tissues in vivo. We have previously shown that OTK18 mRNA is expressed in multiple tissues, including kidney, liver, heart, skeletal muscle, and placenta, but not in peripheral blood leukocytes (Carlson et al. 2004b ). Thus, it is possible that OTK18 is normally secreted from other tissues and is downregulated upon chronic HIV infection. In addition, multiinstitutional international Human Plasma Proteome Project identified 9,052 proteins in plasma samples, of which 196 are zinc finger proteins, accounting 2.2% of total proteins in plasma (Omenn et al. 2005; Ping et al. 2005) . This report strongly supports our data that zinc finger proteins can be detected in human plasma. Further investigation is necessary to identify peripheral OTK18 secretion and its regulation by HIV-1 infection.
